CardioSignal and JISEKI Health advance health equity by introducing a new model in cardiac remote patient monitoring in the USA
CardioSignal, Inc. and JISEKI Health announced their upcoming collaboration. The companies plan to virtualize a care path for earlier detection of heart disease, starting from initial patient engagement, identifying at-risk individuals, and initiating remote patient monitoring. The goal is to improve early detection and health outcomes especially in vulnerable populations.
JISEKI is a Social Determinants of Everything (SDOX) marketplace that delivers always-on safety net triage for service providers across a range of clinical, social, and behavioral services in a highly scalable way. CardioSignal is a health technology company developing digital cardiac biomarkers for heart disease detection using a modern smartphone placed on the chest for one minute.
By combining their technological capabilities, the companies aim to introduce a virtual care model in heart health that can begin from the first patient interaction. The collaboration will begin during the last quarter of 2022.
“We are very excited to partner with CardioSignal. This collaboration will fully integrate our technologies to bring to our patients a digital-first, diagnostically accurate cardiac care experience. JISEKI’s always-on triage and hybrid AI-human concierge support model, will reduce, and in some case eliminate, the time off from work/school/family and transportation burdens Medicaid and Medicare patients experience with routine cardiac screening and monitoring. Not only are we the only digital-first Medicaid provider, but we will be the only digital-first healthcare provider to initiate this novel care solution,” says Jukka Valkonen, RN, PHN, Cofounder and Chief Health Officer from JISEKI Health.
“The disparity in healthcare that favors higher income groups and racial and ethnic majority persists in cardiovascular care. Underserved populations face a higher prevalence of heart disease risk factors, worse outcomes, and mortality. Based on our clinical studies in atrial fibrillation and heart failure, we see a major opportunity in mobile-based models to change this trajectory in widening disparity. This is the promise of healthcare digitalization,” says CardioSignal President, Tero-Pekka Alastalo MD, PhD.
Racial minorities, individuals in rural areas, and lower socio-economic groups are particularly impacted by disparities in heart health. For example, Black Americans are 30% more likely to die from heart disease than white Americans(1). Rural areas have higher death rates for cardiovascular disease and stroke than urban areas(2). In this collaboration, scalability in technology and accessibility in ease-of-use are key in achieving maximum impact.
Focus of Collaboration
JISEKI Health bring individuals direct access to a doctor through text message-based interaction, built for maximized convenience and access
CardioSignal’s platform will be accessed through virtual onboarding that activates the MyCardioSignal mobile app on a patient’s smartphone
A 1-minute measurement with the MyCardioSignal App that measures heart motion in high accuracy will be analyzed
The system will detect signs of irregular rhythm and assess myocardial function to advance earlier detection of heart disease
Further information
CardioSignal Inc, us.cardiosignal.com
Tero-Pekka Alastalo, President, tpa@cardiosignal.com, tel. +1 (650) 285-8564
Juulia Simonen, Director, Brand & Communications, juulia.simonen@cardiosignal.com, +358 50 3059018
JISEKI Health:
Jukka Valkonen, Cofounder and Chief Health Officer, jukka@jisekihealth.com.
About JISEKI Health
JISEKI is a Social Determinants of Everything (SDOX) marketplace that delivers always-on safety net triage for service providers across a range of clinical, social, and behavioral services in a highly scalable way so that everyday people all over the world can become prosperous. www.jisekihealth.com
About CardioSignal
We develop groundbreaking solutions for the detection of heart diseases with digital cardiac biomarkers. CardioSignal utilizes motion sensor technology to non-invasively measure cardiac motion and function. Originally an academic spinoff, the company’s patented technology is built on a decade of research and algorithm development. CardioSignal is a brand and a product by Precordior.
Sources:
1. Singh GK, Siahpush M, Azuine RE, Williams SD. Widening Socioeconomic and Racial Disparities in Cardiovascular Disease Mortality in the United States, 1969-2013. Int J MCH AIDS. 2015;3(2):106-118.
2. Harrington et al. 2020. AHA journals. Call to Action: Rural Health: A Presidential Advisory From the American Heart Association and American Stroke Association
